Patriage / pre-FTO intelligence

The evidence behind your next molecule.

Know where to focus before you invest. Patriage is a pre-FTO (freedom-to-operate) screen: patents, drug registers and market signals in one analyst-reviewed dossier for your generic-drug shortlist.

Start with
One molecule
Pilot delivery
3 business days
Reviewed by
A human analyst
Patriage Illustrative sample

Pre-FTO decision brief

Molecule A

Market access & priorities for review

3Target markets
2Counsel priorities
1Evidence gap
Market assessmentReview priority
  • United KingdomPrioritise review
  • GermanyTiming constraint
  • United StatesEvidence gap
Recommended next step

Focus counsel review on the UK. Resolve the German timing constraint and US evidence gap.

Fictional data · format previewTechMils / 01
A preview of the format. Fictional data, visible reasoning.

The deliverable

A decision brief.
With the working attached.

One PDF per molecule. A clear summary for your team, with the market detail and evidence your counsel needs to take the next step.

Inside the dossier Download sample PDF · 3 pages

Molecule A / sample

Designed for your decision

Read the conclusion. Inspect the evidence. Know what to check next.

Illustrative format with fictional data. This is not a molecule assessment or legal opinion.

Patriage / pre-FTO intelligenceSample · 01 / 03

01 / The decision brief

Decision brief

Molecule A Three markets. Three different next steps.

Analyst summary / illustrative

Prioritise the UK for counsel review. Keep Germany under timing review. Resolve the US source gap before making an investment decision.

01 / Prioritise

United Kingdom

Take the mapped patent position to counsel for a full claim review.

02 / Timing

Germany

Confirm the national extension before selecting a launch window.

03 / Verify

United States

Reconcile the missing register entry before assessing access.

Evidence before investment. Each conclusion leads to a source, a limitation and a named next action.

Fictional data · format previewTechMils / Patriage
Patriage / pre-FTO intelligenceSample · 02 / 03

02 / Market access

Market access assessment

Molecule A / market position Illustrative review windows, not launch clearance.

Fictional Molecule A · dates demonstrate the report format only
MarketReview windowWhat drives the readNext step
United Kingdom UK2028Compound-patent expiry Sample reference S-01Counsel claim review
Germany DE2030National extension Sample reference S-02Confirm extension term
United States USUnresolvedIncomplete register record Sample reference S-03Close the evidence gap

Scroll the table horizontally to inspect all columns

A missing record is an open question. Every date carries its basis and the follow-up needed before it can inform a decision.

Fictional data · format previewTechMils / Patriage
Patriage / pre-FTO intelligenceSample · 03 / 03

03 / Evidence & actions

Evidence & next actions

Molecule A / evidence register Source, limitation and next action stay together.

  1. S-01

    Compound-patent position UK

    Example source: patent-family record and national register.

    Action: Counsel confirms surviving claims and their relevance to the proposed product.

  2. S-02

    National extension DE

    Example source: national supplementary protection certificate register.

    Action: Verify the extension term and any applicable paediatric extension.

  3. S-03

    Register gap US

    Example source: an incomplete drug-register entry.

    Action: Retrieve the missing record and reconcile it with the patent estate.

Sample references · no real patent claimsTechMils / Patriage

This preview shows three selected sections. A full dossier also includes competitors, manufacturing complexity, litigation and safety signals, and the surviving-patents registry.

Request a full sample under NDA

What we examine

Four questions.
A more informed shortlist.

Direct your development and legal budgets toward candidates worth a closer look. Each finding stays connected to its source.

01 / Access

When could each market open?

Compound patents, national extensions and exclusivity, assessed per region and per EU member state. Every proposed date names its basis.

In your dossier Market-opening timeline
02 / Market

Who is already there?

Approved products and labelers across official registers, including US ANDA and NDA counts, European authorisations and UK dispensing.

In your dossier Competitor landscape
03 / Supply

How hard is it to make?

Synthetic-accessibility and chirality flags, alongside API suppliers holding an EDQM Certificate of Suitability.

In your dossier Manufacturing assessment
04 / Risk

What needs a closer look?

Opposition outcomes, litigation and safety signals, and clinical-trial status. Material findings and data gaps are surfaced for review.

In your dossier Risk & evidence register

How it works

Your shortlist in.
A clear next step out.

A managed service, with an analyst in the loop. No software to install or integration to manage.

  1. 01
    You share

    Molecules & markets

    Send your candidates and target regions. We agree the scope and put an NDA in place.

  2. 02
    We examine

    Evidence & exceptions

    Specialist agents cross-check public sources. An analyst reviews the findings and unresolved questions.

  3. 03
    You receive

    A reviewed dossier

    Market timing, competitors and risks, with the sources and follow-up questions ready for your team.

AI does the research legwork. People own the decision. Patriage helps focus a formal FTO review; patent counsel provides the legal opinion.

Where it fits

After the long list.
Before counsel.

Patriage sits between your internal long list and a formal freedom-to-operate opinion. It replaces neither. It shows where the legal budget is best spent.

Before

Many candidates

In-house desk research

What it is
Analysts searching registers one market at a time.
Works well for
A first look at one or two candidates.
You end up with
Notes that vary by analyst and by market.
Patriage

A focused shortlist

A pre-FTO screen

What it is
A managed screen of the whole shortlist, reviewed by an analyst.
Works well for
Deciding which candidates deserve counsel's time.
You end up with
One consistent dossier per molecule, with sources attached.
After

The few you take forward

A formal FTO opinion

What it is
A legal opinion from patent counsel.
Works well for
The candidates you intend to take to market.
You end up with
Legal advice you can rely on.

Who it is for

  • Portfolio and business developmentRank a long list against one evidence standard.
  • IP and regulatory affairsReach counsel with the questions already narrowed.
  • Licensing and partneringCheck a candidate before the conversation starts.

Coverage

Global evidence.
Local context.

Every market is labelled by what its public evidence supports. Coverage is stated explicitly, and data gaps stay visible.

Sources include FDA Orange and Purple Books, EU SPC registers, Health Canada PM(NOC), EPO oppositions, EDQM CEP suppliers, PubChem and ChEMBL.

13 markets: 8 assessed from public register evidence, 5 that need local verification.

  • United StatesAssessed
  • European UnionPer member state
  • United KingdomAssessed
  • CanadaAssessed
  • IndiaAssessed
  • BrazilAssessed
  • South AfricaAssessed
  • WHO PrequalifiedProduct register
  • JapanNot assessed
  • ChinaNot assessed
  • South KoreaNot assessed
  • Gulf / MENANot assessed
  • Rest of worldNot assessed

Pricing

Start with one.
Decide where to go next.

The price depends on how many molecules and markets you need, so every engagement starts with a written quotation, for one report or a portfolio of 10 or more.

01 / Pilot1 report

One full dossier

Evaluate a molecule your team already knows.

On requestTailored quotation3 business days
Ask for a quotation

Every engagement includes

  • Scope, price and delivery date confirmed in writing before work begins
  • Confidentiality agreed before analysis starts
  • One PDF dossier per molecule, with its sources
  • Analyst review of every material finding

A few useful answers

Before you
get started.

Talk to us
What does pre-FTO mean?

FTO stands for freedom to operate: whether a product can be made and sold in a market without infringing someone else's rights. A formal FTO opinion comes from patent counsel. A pre-FTO screen comes first. It gathers the public evidence on patents, exclusivities, approvals and competitors, so you know which molecules and markets are worth that legal review.

Is Patriage a formal freedom-to-operate opinion?

No. Patriage is a pre-FTO intelligence service that assembles evidence and focuses further review. It does not provide legal advice, replace patent counsel or substitute for the studies required to bring a generic to market.

Can I see a full dossier before commissioning a pilot?

Yes. The interactive sample above shows the format using fictional data. Request a full sample under NDA to discuss the depth and evidence with our team.

What data does Patriage use?

Public sources: patent registers, drug registers and scientific databases, listed under Coverage. From you we need only your molecules and target markets, which stay confidential under the arrangements we agree before analysis starts.

What do you need from my team?

Your molecule or shortlist, target markets and any specific questions. We agree the scope and confidentiality arrangements before analysis starts. You do not need to install software.

How do you handle missing or uncertain evidence?

Unresolved records and markets outside assessed coverage are labelled for verification. Each material finding is reviewed by an analyst, with its source and limitations retained in the dossier.

Evaluate Patriage

Put it against a molecule your team already knows.

Start with one candidate and judge the evidence, the boundaries and the usefulness of the final dossier.